focus
Previous article:
FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article: STAT Wunderkinds: Ruey Hu's digital tools for parsing research
Next article: STAT Wunderkinds: Ruey Hu's digital tools for parsing research
entertainment
hotspot
-
Why Sanofi got shellacked over its spinoff
2025-08-26 10:52 -
Diversifying clinical trials isn't enough to close racial gaps: study
2025-08-26 09:58 -
Readout Newsletter: The latest from Bristol, Sarepta, and Novartis
2025-08-26 09:16 -
An exit interview with Bristol Myers Squibb CEO Giovanni Caforio
2025-08-26 09:15 -
Diversifying clinical trials isn't enough to close racial gaps: study
2025-08-26 08:53 -
Hospitals warn Medicare's drug payment fix is ‘unlawful’
2025-08-26 08:22